RETROTOPE completed a Friends and Family preferred round funding in 2008, which was supplemented by additional grant funding in 2009 and 2010. Investors include founders, management, Board members, and highly sophisticated angel investors in life sciences, including northern California’s Life Science Angels. The company completed a first close of additional funding in late 2010. The company now has compelling proof of principle experiments in a number of different disease models of degenerative disease, including model organisms (yeast), cultured human cells, and mammalian disease models. With a final close of the current round, we expect to be able to fund the company through early data in human orphan diseases in CNS and other degenerative conditions. This will be accomplished by working with regulators on approving early clinical trials based on the highly safe profile offered by the company’s deuterated essential nutrients.
Potentially interested new investors should contact Dr. Molinari at the contact information on this web page.